A nasal vaccine candidate based on S2 and N proteins from SARS-CoV-2 generates a broad antibody response systemically and in the lower respiratory tract
{{output}}
Since the beginning of the COVID-19 pandemic, various groups around the world have intensively worked in the development of vaccine candidates against SARS-CoV-2. Several vaccines have been approved in the past years; the majority is based on the Spike or RBD ... ...
